In cardiac amyloidosis, a substantial majority of the patients, 70.4% (88 out of 125), were treated with Tafamidis, a medication specifically targeting transthyretin stabilization to mitigate the progression of amyloidosis. This evidence concerns the gene TTR and cardiac amyloidosis.